Format

Send to

Choose Destination
Cancer Invest. 2009 Oct;27(8):851-6. doi: 10.1080/07357900902744528.

Increased hemoglobin associated with VEGF inhibitors in advanced renal cell carcinoma.

Author information

1
Stanford University School of Medicine, California 94305, USA. laurenhs@stanford.edu

Abstract

We retrospectively analyzed whether increased hemoglobin is a surrogate biomarker of efficacy for vascular endothelial growth factor (VEGF) inhibitors in advanced renal cell carcinoma (RCC) patients. Twelve patients were identified who had received bevacizumab alone or as combination therapy. Eleven patients experienced a rise in hemoglobin. Median change was 1.6 g/dL (0-4.0). Degree of peak increase correlated with longer progression-free survival (PFS) in metastatic patients: increase of < 15% yielded a 3.1-month median PFS compared to 8.2 months with rises > 15%. This study identifies increased hemoglobin as a possible consequence of VEGF inhibitors. The correlation with longer PFS suggests that rise in hemoglobin may be a surrogate biomarker of efficacy.

PMID:
19603304
DOI:
10.1080/07357900902744528
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center